PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen byMartin Kankam, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing two blood-thinning medications, Vicagrel and Clopidogrel, in healthy people who process these drugs differently. The goal is to see how well these medications work in preventing blood clots. Vicagrel is a new medication developed to address the limitations of Clopidogrel.

Research Team

Yanhua Ding

Principal Investigator

Phase I Clinical Research Center of The First Hospital of Jilin University

Youngjun David Kim, MD

Principal Investigator

Altasciences Clinical, Los Angeles

Martin Kankam, MD

Principal Investigator

Altasciences, Kansas City

Eligibility Criteria

Inclusion Criteria

With normal or clinically insignificant abnormal results of physical examination and vital signs test;

Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;

Able to complete the study in compliance with the protocol;

See 4 more

Exclusion Criteria

Positive results from a screen for urine drug test (Morphine, marijuana);

Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;

Consumption of any special diet (such as grapefruit, pitaya, mango, pomelo, etc.) or subjects have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 14 days prior to receiving study drug;

See 19 more